Elutia Inc
NASDAQ:ELUT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Shenzhen Expressway Corp Ltd
SSE:600548
|
CN |
|
Thirdwave Financial Intermediaries Ltd
BSE:531652
|
IN |
|
I
|
Innovaro Inc
OTC:INNI
|
US |
|
Getinge AB
F:GTN0
|
SE |
Elutia Inc
Research & Development
Elutia Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Elutia Inc
NASDAQ:ELUT
|
Research & Development
-$3.8m
|
CAGR 3-Years
26%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
Research & Development
-$523m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-31%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
Elutia Inc
Glance View
Aziyo Biologics, Inc. operates as a biotechnology company. The company is headquartered in Silver Spring, Maryland and currently employs 151 full-time employees. The company went IPO on 2020-10-08. The firm is a commercial-stage company that serves two markets with products based on its biomatrix platforms. The company offers a drug-eluting biologic technology: a fusion of natural biologic material and extended antibiotic release, for device implantation and soft tissue reconstruction. Its first product is CanGaroo Envelope, used for the stabilization of implantable cardiac devices, such as pacemakers and defibrillators. Its second product is SimpliDerm Acellular Dermal Matrix, used primarily in breast reconstruction following mastectomy. The company is also engaged in the development of CanGaroo RM, which adds the antibiotics rifampin and minocycline for sustained delivery directly to the surgical site. The Company’s products are used by electrophysiologists and plastic surgeons.
See Also
What is Elutia Inc's Research & Development?
Research & Development
-3.8m
USD
Based on the financial report for Dec 31, 2024, Elutia Inc's Research & Development amounts to -3.8m USD.
What is Elutia Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-10%
Over the last year, the Research & Development growth was 14%. The average annual Research & Development growth rates for Elutia Inc have been 26% over the past three years , -10% over the past five years .
